drugset / Trial / NCT01737580

Enhancing Influenza Vaccination in Seniors With TLR (Toll Like Receptor) Agonists

NCT01737580

Phase 1 Completed 59 enrolled University of British Columbia
RandomizedParallel-groupTriple-blindTreatment

Summary

The application of the TLR7/8 (Toll Like Receptor) agonist gel (immune response helper) resiquimod will enhance the immune response to the intradermal influenza vaccine in seniors 65-75 years of age.

Timeline

Start
2013-04
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Resiquimod Small molecule Topical

Indications

No indication recorded.